Abstract
Conventional cardiovascular risk assessment is based on traditional risk factors such as serum cholesterol concentrations (cholesterol, HDL cholesterol, LDL cholesterol) and blood pressure levels. It is becoming increasingly clear that the newer laboratory measures may help to refine risk estimates in the general population. In a recent publication of the MONICA5 (Monitoring of Trends and Determinants of Cardiovascular Disease) investigators 1, Blankenberg and colleagues evaluated the potential contribution of 30 novel biomarkers to the 10-year cardiovascular disease risk in 2 population cohorts. These biomarkers were part of the MORGAM (MONICA, Risk, Genetics, Archiving, and Monograph) Biomarker Project and were representative of 9 distinct metabolic processes linked to atherosclerosis 2. They include ( a ) lipid-related biomarkers, ( b ) renal function markers, ( c ) metabolic markers representing glucose and obesity pathways, ( d ) markers of vascular function and neurohumoral activity, ( e ) inflammation markers, ( f ) markers of oxidative stress and antioxidants, ( g ) coagulation markers, ( h ) angiogenesis markers, and ( i ) necrosis markers. In addition to the inclusion of a large number of biomarkers for assessment, this study was based on a highly standardized and comprehensive quality control and assurance program implemented on clinical laboratory instruments. All analyses were …
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
